Company Filing History:
Years Active: 2024-2025
Title: Innovations and Contributions of Sebastian Meier-Ewert
Introduction
Sebastian Meier-Ewert is a notable inventor based in Martinsried, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic strategies. With a total of 3 patents to his name, his work focuses on addressing critical challenges in treating proliferative diseases.
Latest Patents
One of his latest patents is titled "Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof." This invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. The patent provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors. It also includes methods for sensitizing cells involved with proliferative disorders against the cytotoxic effects of certain pro-inflammatory signaling pathways. Additionally, the invention outlines diagnostic, prognostic, and monitoring methods based on the detection of SIK3 in samples obtained from subjects.
Another significant patent by Meier-Ewert is "Heterocyclic kinase inhibitors and uses thereof." This invention relates to kinase inhibitors, particularly those targeting protein kinases, including the protein-tyrosine kinases LCK, ABL, SRC, KIT, and SIK-family. The patent describes pharmaceutical compositions that comprise these kinase inhibitors, which may be used in treating disorders such as leukemia or solid tumors. The invention emphasizes the potential for these inhibitors to be used in combination treatment regimens alongside other therapeutic agents.
Career Highlights
Sebastian Meier-Ewert is currently associated with Iomx Therapeutics AG, where he continues to innovate and develop new therapeutic solutions. His work is characterized by a strong focus on the intersection of molecular biology and pharmacology, aiming to improve treatment outcomes for patients with challenging medical conditions.
Collaborations
Throughout his career, Meier-Ewert has collaborated with notable colleagues, including Nisit Khandelwal and Peter Sennhenn. These collaborations have further enriched his research and contributed to the advancement of therapeutic strategies in the field.
Conclusion
Sebastian Meier-Ewert's contributions to biotechnology and his innovative patents highlight his commitment to improving treatment options for proliferative diseases. His work continues to inspire advancements in medical research and therapeutic development.